Rouvier Al-Monajjed
Overview
Explore the profile of Rouvier Al-Monajjed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hubner A, Busshoff I, Lakes J, Al-Monajjed R, Radtke J, Albers P
Urologie
. 2024 Nov;
64(1):14-23.
PMID: 39609267
Background: Population-based screening for prostate cancer (PC) is still controversially discussed. Furthermore, an organized, risk-adapted screening program is already being called for across Europe. Although large randomized controlled trials have...
2.
Al-Monajjed R, Albers P, Droop J, Fugmann D, Noldus J, Palisaar R, et al.
Trials
. 2024 Nov;
25(1):754.
PMID: 39533412
Background: With over 65,000 new cases per year in Germany, prostate cancer (PC) is the most common cancer in men in Germany. Localized PC is often treated by radical prostatectomy...
3.
De Vrieze M, Al-Monajjed R, Boschheidgen M, Albers P
J Pers Med
. 2024 Aug;
14(8).
PMID: 39202010
Prostate cancer (PCa) screening strategies are being developed and evaluated in several countries. However, most of the evidence regarding PCa screening has been generated in study populations aged 50 and...
4.
De Vrieze M, Hubner A, Al-Monajjed R, Albers P, Radtke J, Schimmoller L, et al.
Radiologie (Heidelb)
. 2024 Jun;
64(7):545.
PMID: 38884640
No abstract available.
5.
De Vrieze M, Hubner A, Al-Monajjed R, Albers P, Radtke J, Schimmoller L, et al.
Radiologie (Heidelb)
. 2024 May;
64(6):479-487.
PMID: 38743100
Background: The harm-to-benefit ratio of prostate cancer (PCa) screening remains controversial mainly due to the unfavorable test characteristics of prostate-specific antigen (PSA) as a screening test. Methods: In this nonsystematic...
6.
Thiel T, Valentin B, Ullrich T, Boschheidgen M, Schimmoller L, Benkert T, et al.
J Magn Reson Imaging
. 2024 Apr;
61(1):512-515.
PMID: 38581176
No abstract available.
7.
Boschheidgen M, Ullrich T, Al-Monajjed R, Ziayee F, Michalski R, Steuwe A, et al.
Sci Rep
. 2024 Apr;
14(1):7758.
PMID: 38565890
Knowledge about anatomical details seems to facilitate the procedure and planning of prostatic artery embolization (PAE) in patients with symptomatic benign prostatic hyperplasia (BPS). The aim of our study was...
8.
Valentin B, Arsov C, Ullrich T, Al-Monajjed R, Boschheidgen M, Hadaschik B, et al.
Eur Urol Open Sci
. 2024 Feb;
59:30-38.
PMID: 38298772
Background: Multiparametric magnetic resonance imaging (mpMRI) may allow patients with prostate cancer (PC) on active surveillance (AS) to avoid repeat prostate biopsies during monitoring. Objective: To assess the ability of...
9.
Wolframm B, Hubner A, Handke A, Bushoff I, Lakes J, Al-Monajjed R, et al.
Urologie
. 2023 May;
62(7):727-729.
PMID: 37233788
No abstract available.
10.
Boschheidgen M, Al-Monajjed R, Minko P, Jannusch K, Ullrich T, Radke K, et al.
CVIR Endovasc
. 2023 Mar;
6(1):9.
PMID: 36859572
Background: To investigate the influence of benign prostatic hyperplasia (BPH) patterns detected with MRI on clinical outcomes after prostatic artery embolization (PAE). Materials & Methods: This retrospective study included 71 ...